CHC

The research team at CHC focuses on innovative treatments for inflammatory bowel conditions, including ulcerative colitis and Crohn’s disease. Studies aim to evaluate new drug candidates and biological strategies to reduce disease activity and prevent postoperative recurrence.

• Ulcerative colitis – novel oral therapy evaluation
• Crohn’s disease – postoperative biological treatment strategies
• Endoscopic recurrence monitoring after ileocolonic resection

The department leverages its expertise in gastroenterology to advance patient‑centered care and improve long‑term outcomes for individuals living with chronic digestive disorders.

At CHC, investigators are exploring therapies to protect the lungs of extremely preterm infants at risk of Bronchopulmonary Dysplasia. Projects assess the safety of intratracheal EXOB-001 and the potential of mesenchymal‑derived extracellular vesicles to prevent this severe neonatal lung disease.

• Bronchopulmonary Dysplasia – prevention with mesenchymal extracellular vesicles
• Safety assessment of intratracheal EXOB-001 in preterm newborns
• Neonatal lung injury therapeutic development

The respiratory research program integrates neonatal intensive care expertise to develop safer, more effective interventions for vulnerable newborns.